Loading stock data…
MLYS
$29.26+2.61 (+9.79%)
Market ClosedLast close May 1
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mineralys Therapeutics, Inc. in the Healthcare sector is trading at $29.26. The stock is currently 39% below its 52-week high of $47.65, remaining 5.6% below its 200-day moving average. Technical signals show neutral RSI of 58 and bearish MACD signal, explaining why MLYS maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.26
Potential Upside
5%
Whystock Fair Value$30.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.91%
Volume
Today's trading volume
2.09M
Recent News
Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 Best New Stocks to Invest In According to Hedge Funds. Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best new stocks to invest in according to hedge funds. On March 24, Mineralys Therapeutics appointed Jeffrey A. Munsie as Chief Legal Officer to oversee the company’s legal […]
Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy?
Mineralys Therapeutics recently appointed Jeffrey A. Munsie as Chief Legal Officer, adding nearly 25 years of biopharma legal experience as the company advances lorundrostat for cardiorenal conditions including hypertension, chronic kidney disease and obstructive sleep apnea. This hire complements the FDA’s acceptance of the lorundrostat New Drug Application for hypertension, highlighting Mineralys’ preparation for potential commercialization and expansion into additional indications. We’ll...
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds. On March 13, Bank of America Securities maintained a Buy rating on Mineralys Therapeutics Inc. (NASDAQ:MLYS). The firm increased its price target to $51 from $46, citing recent updates on the clinical development progress of its […]
Immunic appoints biopharmaceutical executive Jon Congleton to board
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program through late-stage development. Congleton brings nearly four decades of experience in the...